These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 3719855)

  • 1. Dialyzability of cefotaxime and mecillinam.
    el-Guinedy M; el Said W; Sabbour MS
    Chemioterapia; 1986 Jun; 5(3):208-12. PubMed ID: 3719855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doses of antibiotic in patients with renal insufficiency.
    Ohkawa M; Kuroda K
    Clin Ther; 1981; 4 Suppl A():124-32. PubMed ID: 6275994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose kinetics and dosage of mecillinam in renal failure and haemodialysis.
    Schapira A
    Clin Pharmacokinet; 1984; 9(4):364-70. PubMed ID: 6088153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of intravenous cefotaxime in patients undergoing chronic hemodialysis.
    Chodos J; Francke EL; Saltzman M; Neu HC
    Ther Drug Monit; 1981; 3(1):71-4. PubMed ID: 6262952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of catheter-restricted filling with cefotaxime and heparin on the lifespan of temporary hemodialysis catheters: a case controlled study.
    Saxena AK; Panhotra BR
    J Nephrol; 2005; 18(6):755-63. PubMed ID: 16358235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.
    Vanholder R; Camez A; Veys N; Van Loo A; Dhondt AM; Ringoir S
    Thromb Haemost; 1997 Apr; 77(4):650-5. PubMed ID: 9134637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ceftizoxime in patients undergoing hemodialysis.
    Shah PM; Knobloch M; Haag R; Kühnle HF
    Methods Find Exp Clin Pharmacol; 1982; 4(3):185-8. PubMed ID: 6289027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative characteristics of the methods for assessing aminoglycoside extraction with the artificial kidney tobramycin clearance and dialyzability].
    Firsov AA; Bogomolova NS; Treskina OS; Belorusov OS; Egorenko GG
    Antibiotiki; 1981 Apr; 26(4):290-7. PubMed ID: 7235670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of dyphylline elimination by uremic patients.
    Lee CC; Wang LH; Majeske BL; Marbury TC
    J Pharmacol Exp Ther; 1981 May; 217(2):340-4. PubMed ID: 7229976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A
    J Ayub Med Coll Abbottabad; 2004; 16(2):3-8. PubMed ID: 15455608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodialysis clearance of ethosuximide in patients with chronic renal disease.
    Marbury TC; Lee CS; Perchalski RJ; Wilder BJ
    Am J Hosp Pharm; 1981 Nov; 38(11):1757-60. PubMed ID: 7304633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of hemodialysis on ceftazidime pharmacokinetics.
    Nikolaidis P; Tourkantonis A
    Clin Nephrol; 1985 Sep; 24(3):142-6. PubMed ID: 3899438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefotaxime disposition pharmacokinetics during peritoneal dialysis.
    Overgaard S; Løkkegaard N; Scrøder S; Fugleberg S; Nielsen-Kudsk F
    Pharmacol Toxicol; 1987 May; 60(5):321-4. PubMed ID: 3615340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of anakinra in subjects with different levels of renal function.
    Yang BB; Baughman S; Sullivan JT
    Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dialysis treatment of acute chromium intoxication and comparative efficacy of peritoneal versus hemodialysis in chromium removal.
    Schiffl H; Weidmann P; Weiss M; Massry SG
    Miner Electrolyte Metab; 1982 Jan; 7(1):28-35. PubMed ID: 7169974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical report on hemodialysis in the Department of Transplantation, Tokai University School of Medicine.
    Hida M; Saitoh H; Shiramizu T; Nakamura K; Shinbo T; Nakayama M; Satoh T
    Tokai J Exp Clin Med; 1981 Jul; 6(3):247-57. PubMed ID: 7303005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of tubular anion and cation secretion to residual renal function in chronic dialysis patients.
    van Olden RW; van Acker BA; Koomen GC; Krediet RT; Arisz L
    Clin Nephrol; 1998 Mar; 49(3):167-72. PubMed ID: 9543598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetics of cefotaxime in patients with chronic renal impairment (author's transl)].
    Fillastre JP; Ings RM; Leroy A; Humbert G; Godin M
    Nouv Presse Med; 1981 Feb; 10(8):574-9. PubMed ID: 6259595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetics of trimethoprim and sulfametrol in patients with end stage renal failure and hemodialysis treatment (author's transl)].
    Schmidt P; Korn A; Hitzenberger G; Zazgornik J; Kopsa H; Pils P
    Wien Med Wochenschr; 1980 Feb; 130(4):171-3. PubMed ID: 7376686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.